Acute Ischemic Stroke Therapeutics Market: Growth Opportunities led by Athersys Inc. and Bayer AG - Technavio - Yahoo Finance
NEW YORK, Nov. 28, 2022 /PRNewswire/ -- The acute ischemic stroke (AIS) therapeutics market size is estimated to grow by USD 1,524.49 million during 2022-2027, at a CAGR of 5.72%. The growth of the market will be driven by the rising prevalence of high-risk factors. Furthermore, the use of technologies such as TBI is expected to boost market growth.
The report extensively covers the acute ischemic stroke (AIS) therapeutics market segmentation by type (thrombolytic, anticoagulants, antiplatelets, and antihypertensives), distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW). Request a Free Sample Report
Acute Ischemic Stroke Therapeutics Market - Vendors
The global AIS therapeutics market is a fragmented market, with the presence of various large and small players. Large players are focusing on consolidating the market through increased strategic alliances and acquisitions to increase their market shares. In addition, these vendors are continuously innovating their offerings. Some of the key vendors are listed below:
Athersys Inc.
Bayer AG
Biogen Inc.
Boehringer Ingelheim International GmbH
Medtronic Plc
NoNO Inc.
SanBio Co Ltd.
Stryker Corp.
Amgen Inc.
AstraZeneca Plc
Bristol Myers Squibb Co.
Daiichi Sankyo Co. Ltd.
F. Hoffmann La Roche Ltd.
Johnson & Johnson
Merck & Co. Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Product Insights and News
• athersys.com: The company offers acute ischemic stroke therapeutics such as Repatha.
• bayer.com - The company offers acute ischemic stroke therapeutics such as BRILINTA ticagrelor tablets.
• biogen.com - The company offers acute ischemic stroke therapeutics such as Masters 2 MultiStem cell therapy.
For detailed insights about product offerings and the growth strategies adopted by vendors, buy the report.
Acute Ischemic Stroke Therapeutics Market - Geographical Landscape
North America is estimated to account for 38% of the market's growth during the forecast period. The growth of the market in this region is attributed to factors such as the expected approval of late-stage pipeline molecules, including BIIB093 (intravenous glibenclamide), BRILINTA, MultiStem, and NA-1. In addition, the region is expected to witness the availability of various diagnostics and drugs for the treatment of stroke, which will drive market growth.
Acute Ischemic Stroke Therapeutics Market - Market Segmentation
The thrombolytics segment is estimated to contribute the highest share of the global market's growth during the forecast period. One of the factors behind the growth of this segment is the availability of US FDA-approved therapeutic treatments for AIS. For instance, the IV alteplase drug is sold under the brand name Activase. It is a tissue plasminogen activator and is used for multiple indications such as AIS, acute myocardial infarction (AMI), and acute massive pulmonary embolism (PE). Download a free sample report
What are the key data covered in this acute ischemic stroke (AIS) therapeutics market report?
CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the acute ischemic stroke (AIS) therapeutics market between 2023 and 2027
Precise estimation of the size of the acute ischemic stroke (AIS) therapeutics market size and its contribution to the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the acute ischemic stroke (AIS) therapeutics market across APAC, North America, Europe, Middle East and Africa, and South America
Thorough analysis of the market's competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of acute ischemic stroke (AIS) therapeutics market vendors
Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights
Related Reports:
APAC Acute Myeloid Leukemia (AML) Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The acute myeloid leukemia (AML) treatment market size in APAC is projected to grow by USD 277.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.83%.
Alzheimer's Disease Therapeutics Market by Drug Class and Geography - Forecast and Analysis 2022-2026: The Alzheimer's disease therapeutics market size is projected to grow by USD 3.99 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.76%.
Acute Ischemic Stroke Therapeutics Market Scope | |
Report Coverage | Details |
Page number | 120 |
Base year | 2022 |
Historic Period | 2017-2021 |
Forecast period | 2023-2027 |
Growth momentum & CAGR | Accelerate at a CAGR of 5.72% |
Market growth 2023-2027 | USD 1524.49 million |
Market structure | Fragmented |
YoY growth (%) | 5.49 |
Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution | North America at 38% |
Key consumer countries | US, Canada, UK, Germany, and China |
Competitive landscape | Leading companies, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Companies profiled | Athersys Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Medtronic Plc, NoNO Inc., SanBio Co Ltd., Stryker Corp., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd. |
Market Dynamics | Parent Market Analysis; Market growth inducers and obstacles; Fast-growing and slow-growing segment analysis for the forecast period |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio "Health Care" Research Reports
Table of Contents
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.3 Market size 2022
4 Five Forces Analysis
4.1 Five forces summary
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Type
5.1 Market segments
5.2 Comparison by Type
6 Market Segmentation by Distribution Channel
6.1 Market segments
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
9.1 Market drivers
9.2 Market challenges
9.4 Market trends
10 Vendor Landscape
10.1 Overview
10.2 Vendor landscape
10.4 Industry risks
11 Vendor Analysis
11.1 Vendors covered
11.3 Amgen Inc.
11.4 AstraZeneca Plc
11.5 Athersys Inc.
11.6 Bayer AG
11.7 Biogen Inc.
11.13 Medtronic Plc
11.14 Merck and Co. Inc.
11.15 Pfizer Inc.
11.16 Sanofi SA
12 Appendix
12.1 Scope of the report
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/acute-ischemic-stroke-therapeutics-market-growth-opportunities-led-by-athersys-inc-and-bayer-ag---technavio-301687079.html
SOURCE Technavio
Comments
Post a Comment